Annual report
4078.TEDINET S100PZW9
Period2019-04-01 → 2020-03-31
Filed2023-01-23
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amends S100IYJA.
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥87.2bn | 2019-04-01 → 2020-03-31 | Cons. | Net sales |
| Revenue | ¥89.5bn | 2018-04-01 → 2019-03-31 | Cons. | Net sales |
| Revenue | ¥87.2bn | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥83.9bn | 2016-04-01 → 2017-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥85.5bn | 2015-04-01 → 2016-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥4.0bn | 2019-04-01 → 2020-03-31 | Cons. | Operating income |
| Operating income | ¥4.4bn | 2018-04-01 → 2019-03-31 | Cons. | Operating income |
| Ordinary income | ¥4.2bn | 2019-04-01 → 2020-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.6bn | 2018-04-01 → 2019-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.3bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.3bn | 2016-04-01 → 2017-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.4bn | 2015-04-01 → 2016-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥4.0bn | 2019-04-01 → 2020-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥5.2bn | 2018-04-01 → 2019-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.5bn | 2019-04-01 → 2020-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.6bn | 2018-04-01 → 2019-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.3bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.0bn | 2016-04-01 → 2017-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.3bn | 2015-04-01 → 2016-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.7bn | 2019-04-01 → 2020-03-31 | Cons. | Profit loss |
| Net income | ¥3.8bn | 2018-04-01 → 2019-03-31 | Cons. | Profit loss |
| Total assets | ¥121.6bn | at 2020-03-31 | Cons. | Assets |
| Total assets | ¥120.1bn | at 2019-03-31 | Cons. | Assets |
| Total assets | ¥117.5bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥120.3bn | at 2017-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥117.7bn | at 2016-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥40.2bn | at 2020-03-31 | Cons. | Liabilities |
| Total liabilities | ¥39.8bn | at 2019-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥81.5bn | at 2020-03-31 | Cons. | Net assets |
| Net assets / equity | ¥80.3bn | at 2019-03-31 | Cons. | Net assets |
| Net assets / equity | ¥80.8bn | at 2018-03-31d | Cons. | Net assets |
| Net assets / equity | ¥81.9bn | at 2017-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥79.6bn | at 2016-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.1bn | at 2020-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥11.2bn | at 2019-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥9.1bn | at 2020-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.2bn | at 2019-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.8bn | at 2018-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.6bn | at 2017-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥13.8bn | at 2016-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥6.5bn | 2019-04-01 → 2020-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.8bn | 2018-04-01 → 2019-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.9bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.7bn | 2016-04-01 → 2017-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.6bn | 2015-04-01 → 2016-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥8.4bn | 2019-04-01 → 2020-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5.5bn | 2018-04-01 → 2019-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥487m | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.8bn | 2016-04-01 → 2017-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.5bn | 2015-04-01 → 2016-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥68m | 2019-04-01 → 2020-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥64m | 2018-04-01 → 2019-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.2bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.0bn | 2016-04-01 → 2017-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.4bn | 2015-04-01 → 2016-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥150.84 | 2019-04-01 → 2020-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥210.34 | 2018-04-01 → 2019-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥130.29 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥109.59 | 2016-04-01 → 2017-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥121.82 | 2015-04-01 → 2016-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥4,657.04 | at 2020-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,598.89 | at 2019-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,450.92 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,329.25 | at 2017-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,075.2 | at 2016-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 64.4% | at 2020-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.3% | at 2019-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.3% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.9% | at 2017-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.4% | at 2016-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 3.3% | 2019-04-01 → 2020-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.6% | 2018-04-01 → 2019-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.0% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.6% | 2016-04-01 → 2017-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.0% | 2015-04-01 → 2016-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 2,003 | at 2020-03-31 | Cons. | Number of employees |
| Employees | 1,964 | at 2019-03-31 | Cons. | Number of employees |
| Employees | 1,875 | at 2018-03-31d | Cons. | Number of employees |
| Employees | 1,870 | at 2017-03-31d | Cons. | Number of employees |
| Employees | 1,796 | at 2016-03-31d | Cons. | Number of employees |
| Revenue | ¥37.0bn | 2019-04-01 → 2020-03-31 | Standalone | Net sales |
| Revenue | ¥40.6bn | 2018-04-01 → 2019-03-31 | Standalone | Net sales |
| Revenue | ¥38.8bn | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥36.4bn | 2016-04-01 → 2017-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥35.2bn | 2015-04-01 → 2016-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥419m | 2019-04-01 → 2020-03-31 | Standalone | Operating income |
| Operating income | ¥1.1bn | 2018-04-01 → 2019-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.0bn | 2019-04-01 → 2020-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.2bn | 2018-04-01 → 2019-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥3.0bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.8bn | 2016-04-01 → 2017-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2015-04-01 → 2016-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.8bn | 2019-04-01 → 2020-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.3bn | 2018-04-01 → 2019-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.6bn | 2019-04-01 → 2020-03-31 | Standalone | Profit loss |
| Net income | ¥2.0bn | 2018-04-01 → 2019-03-31 | Standalone | Profit loss |
| Net income | ¥3.3bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.7bn | 2016-04-01 → 2017-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.4bn | 2015-04-01 → 2016-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥88.7bn | at 2020-03-31 | Standalone | Assets |
| Total assets | ¥84.6bn | at 2019-03-31 | Standalone | Assets |
| Total assets | ¥81.7bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥82.8bn | at 2017-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥79.4bn | at 2016-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥33.3bn | at 2020-03-31 | Standalone | Liabilities |
| Total liabilities | ¥29.3bn | at 2019-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥55.5bn | at 2020-03-31 | Standalone | Net assets |
| Net assets / equity | ¥55.3bn | at 2019-03-31 | Standalone | Net assets |
| Net assets / equity | ¥57.6bn | at 2018-03-31d | Standalone | Net assets |
| Net assets / equity | ¥58.0bn | at 2017-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥56.3bn | at 2016-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.5bn | at 2020-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.2bn | at 2019-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥92.38 | 2019-04-01 → 2020-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥114.76 | 2018-04-01 → 2019-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥183.6 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.25 | 2016-04-01 → 2017-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.01 | 2015-04-01 → 2016-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥40 | 2019-04-01 → 2020-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2018-04-01 → 2019-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥8 | 2016-04-01 → 2017-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥8 | 2015-04-01 → 2016-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,297.38 | at 2020-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,293.74 | at 2019-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,287.96 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,168.42 | at 2017-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,978.8 | at 2016-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 62.5% | at 2020-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.4% | at 2019-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.5% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.1% | at 2017-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.9% | at 2016-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 2.8% | 2019-04-01 → 2020-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.5% | 2018-04-01 → 2019-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.9% | 2016-04-01 → 2017-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.5% | 2015-04-01 → 2016-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 17,000,000 | at 2020-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,000,000 | at 2019-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 20,987,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 104,939,000 | at 2017-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 104,939,000 | at 2016-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 776 | at 2020-03-31 | Standalone | Number of employees |
| Employees | 768 | at 2019-03-31 | Standalone | Number of employees |
| Employees | 739 | at 2018-03-31d | Standalone | Number of employees |
| Employees | 719 | at 2017-03-31d | Standalone | Number of employees |
| Employees | 710 | at 2016-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 57
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2019-04-01 → 2020-03-31 | ¥80m |
| Reconciling Itemsreconciling | depreciation | 2019-04-01 → 2020-03-31 | ¥143m |
| Reconciling Itemsreconciling | revenue | 2019-04-01 → 2020-03-31 | −¥1.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2019-04-01 → 2020-03-31 | −¥1.6bn |
| Reconciling Itemsreconciling | segment assets | at 2020-03-31 | ¥11.9bn |
| Reconciling Itemsreconciling | segment profit | 2019-04-01 → 2020-03-31 | −¥2.2bn |
| Chemicalreportable segment | capex | 2019-04-01 → 2020-03-31 | ¥8.7bn |
| Chemicalreportable segment | depreciation | 2019-04-01 → 2020-03-31 | ¥3.3bn |
| Chemicalreportable segment | employees | at 2020-03-31 | 1650 pure |
| Chemicalreportable segment | revenue | 2019-04-01 → 2020-03-31 | ¥79.9bn |
| Chemicalreportable segment | revenue external | 2019-04-01 → 2020-03-31 | ¥78.6bn |
| Chemicalreportable segment | revenue intersegment | 2019-04-01 → 2020-03-31 | ¥1.4bn |
| Chemicalreportable segment | segment assets | at 2020-03-31 | ¥95.9bn |
| Chemicalreportable segment | segment profit | 2019-04-01 → 2020-03-31 | ¥5.6bn |
| Medicine And Healthcarereportable segment | capex | 2019-04-01 → 2020-03-31 | ¥320m |
| Medicine And Healthcarereportable segment | depreciation | 2019-04-01 → 2020-03-31 | ¥199m |
| Medicine And Healthcarereportable segment | employees | at 2020-03-31 | 278 pure |
| Medicine And Healthcarereportable segment | revenue | 2019-04-01 → 2020-03-31 | ¥8.8bn |
| Medicine And Healthcarereportable segment | revenue external | 2019-04-01 → 2020-03-31 | ¥8.6bn |
| Medicine And Healthcarereportable segment | revenue intersegment | 2019-04-01 → 2020-03-31 | ¥201m |
| Medicine And Healthcarereportable segment | segment assets | at 2020-03-31 | ¥13.9bn |
| Medicine And Healthcarereportable segment | segment profit | 2019-04-01 → 2020-03-31 | ¥594m |
| —segment total | capex | 2019-04-01 → 2020-03-31 | ¥9.1bn |
| —segment total | depreciation | 2019-04-01 → 2020-03-31 | ¥3.5bn |
| —segment total | revenue | 2019-04-01 → 2020-03-31 | ¥88.7bn |
| —segment total | revenue external | 2019-04-01 → 2020-03-31 | ¥87.2bn |
| —segment total | revenue intersegment | 2019-04-01 → 2020-03-31 | ¥1.6bn |
| —segment total | segment assets | at 2020-03-31 | ¥109.7bn |
| —segment total | segment profit | 2019-04-01 → 2020-03-31 | ¥6.2bn |
| Reconciling Itemsreconciling | capex | 2018-04-01 → 2019-03-31 | ¥22m |
| Reconciling Itemsreconciling | depreciation | 2018-04-01 → 2019-03-31 | ¥145m |
| Reconciling Itemsreconciling | revenue | 2018-04-01 → 2019-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2018-04-01 → 2019-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | segment assets | at 2019-03-31 | ¥14.5bn |
| Reconciling Itemsreconciling | segment profit | 2018-04-01 → 2019-03-31 | −¥2.3bn |
| Chemicalreportable segment | capex | 2018-04-01 → 2019-03-31 | ¥7.6bn |
| Chemicalreportable segment | depreciation | 2018-04-01 → 2019-03-31 | ¥2.9bn |
| Chemicalreportable segment | revenue | 2018-04-01 → 2019-03-31 | ¥82.5bn |
| Chemicalreportable segment | revenue external | 2018-04-01 → 2019-03-31 | ¥81.3bn |
| Chemicalreportable segment | revenue intersegment | 2018-04-01 → 2019-03-31 | ¥1.2bn |
| Chemicalreportable segment | segment assets | at 2019-03-31 | ¥92.1bn |
| Chemicalreportable segment | segment profit | 2018-04-01 → 2019-03-31 | ¥6.3bn |
| Medicine And Healthcarereportable segment | capex | 2018-04-01 → 2019-03-31 | ¥220m |
| Medicine And Healthcarereportable segment | depreciation | 2018-04-01 → 2019-03-31 | ¥180m |
| Medicine And Healthcarereportable segment | revenue | 2018-04-01 → 2019-03-31 | ¥8.4bn |
| Medicine And Healthcarereportable segment | revenue external | 2018-04-01 → 2019-03-31 | ¥8.3bn |
| Medicine And Healthcarereportable segment | revenue intersegment | 2018-04-01 → 2019-03-31 | ¥141m |
| Medicine And Healthcarereportable segment | segment assets | at 2019-03-31 | ¥13.6bn |
| Medicine And Healthcarereportable segment | segment profit | 2018-04-01 → 2019-03-31 | ¥376m |
| —segment total | capex | 2018-04-01 → 2019-03-31 | ¥7.8bn |
| —segment total | depreciation | 2018-04-01 → 2019-03-31 | ¥3.0bn |
| —segment total | revenue | 2018-04-01 → 2019-03-31 | ¥90.9bn |
| —segment total | revenue external | 2018-04-01 → 2019-03-31 | ¥89.5bn |
| —segment total | revenue intersegment | 2018-04-01 → 2019-03-31 | ¥1.4bn |
| —segment total | segment assets | at 2019-03-31 | ¥105.6bn |
| —segment total | segment profit | 2018-04-01 → 2019-03-31 | ¥6.7bn |
| Chemicalreportable segment | employees | at 2020-03-31 | 701 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,837
| Item | Context | Value | Unit |
|---|---|---|---|
| Increase decrease in net defined benefit liability ope cf | Prior1YearDuration | 80000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | CurrentYearDuration | 102000000 | JPY |
| Loss gain on valuation of investment securities ope cf | Prior1YearDuration | 72000000 | JPY |
| Loss gain on valuation of investment securities ope cf | CurrentYearDuration | 275000000 | JPY |
| Interest and dividends income ope cf | Prior1YearDuration | -275000000 | JPY |
| Interest and dividends income ope cf | CurrentYearDuration | -268000000 | JPY |
| Interest expenses ope cf | Prior1YearDuration | 91000000 | JPY |
| Interest expenses ope cf | CurrentYearDuration | 83000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YearDuration | 106000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYearDuration | 2552000000 | JPY |
| Decrease increase in inventories ope cf | Prior1YearDuration | -2740000000 | JPY |
| Decrease increase in inventories ope cf | CurrentYearDuration | -2367000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YearDuration | 210000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYearDuration | -968000000 | JPY |
| Other net ope cf | Prior1YearDuration | -1198000000 | JPY |
| Other net ope cf | CurrentYearDuration | 503000000 | JPY |
| Subtotal ope cf | Prior1YearDuration | 4676000000 | JPY |
| Subtotal ope cf | CurrentYearDuration | 7231000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YearDuration | 274000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYearDuration | 269000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YearDuration | -91000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYearDuration | -83000000 | JPY |
| Income taxes paid ope cf | Prior1YearDuration | -2103000000 | JPY |
| Income taxes paid ope cf | CurrentYearDuration | -962000000 | JPY |
| Net cash provided by used in operating activities | Prior1YearDuration | 2755000000 | JPY |
| Net cash provided by used in operating activities | CurrentYearDuration | 6454000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YearDuration | -6891000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYearDuration | -8403000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1YearDuration | 1516000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYearDuration | 17000000 | JPY |
| Purchase of investment securities inv cf | Prior1YearDuration | -40000000 | JPY |
| Purchase of investment securities inv cf | CurrentYearDuration | -201000000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1YearDuration | 681000000 | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYearDuration | 411000000 | JPY |
| Collection of loans receivable inv cf | Prior1YearDuration | 107000000 | JPY |
| Collection of loans receivable inv cf | CurrentYearDuration | 63000000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1YearDuration | -702000000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | CurrentYearDuration | － | JPY |
| Other net inv cf | Prior1YearDuration | -129000000 | JPY |
| Other net inv cf | CurrentYearDuration | -312000000 | JPY |
| Net cash provided by used in investment activities | Prior1YearDuration | -5458000000 | JPY |
| Net cash provided by used in investment activities | CurrentYearDuration | -8424000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YearDuration | -2824000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYearDuration | 174000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YearDuration | 7900000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYearDuration | 1500000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YearDuration | -2116000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYearDuration | -1031000000 | JPY |
| Purchase of treasury stock fin cf | Prior1YearDuration | -2001000000 | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration | -0 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |